<DOC>
	<DOCNO>NCT01332942</DOCNO>
	<brief_summary>The drug investigation study BAY85-3934 intend use treatment patient suffer renal anemia due chronic kidney disease ( stage 3 4 ) . The purpose study provide safety tolerability information drug . Other objective study investigate effect drug body ( pharmacodynamics ) well absorption , breakdown , metabolism , distribution excretion ( pharmacokinetics ) measure concentration blood urine . The study conduct one study center United Kingdom several center Germany . 84 ( 36 optional ) patient meet inclusion criterion participate study . BAY 85-3934 give follow combine single / multiple dose escalation design seven ( three optional ) dose step .</brief_summary>
	<brief_title>Combined Single / Multiple Dose Escalation Study Patients With Renal Anemia Due CKD ( Chronic Kidney Disease )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>The informed consent must sign study specific test procedures do Renal anemia due CKD ( stage 3 4 ) dialysis assess medical history Creatine Clearance ( CLCR ) 15 59 mL/min ± 10 % ( ie CLCR 13 65 mL/min ) estimate prestudy visit creatinine concentration measure serum ( Modification Diet Renal Disease ( MDRD ) formula ) Stable renal disease , ie without major change therapy within last 6 week expect begin dialysis within study . Female subject childbearing potential ( postmenopausal woman 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 30 mIU/mL , woman 6 week post bilateral ovariectomy , woman bilateral tubal ligation , woman hysterectomy ) . Male subject agree use two form effective contraception study 12 week receive study drug . This must include condom spermicide gel 21 day drug administration . Male subject agree act sperm donor 12 week dose . Age : ≥ 18 ≤ 85 year prestudy visit Body mass index ( BMI ) : ≥ 18 ≤ 35 kg / m2 prestudy visit Hemoglobin ( Hb ) 8.0 12 g/dL ( male ) 8.0 11.5 g/dL ( female ) two consecutive measurement ( 1 measurement perform within 12 week 2 day prestudy visit routine diagnostics independently study 1 measurement prestudy visit ) Ability understand follow studyrelated instruction Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Known hypersensitivity study drug ( active substance excipients preparation ) Known severe allergy , nonallergic drug reaction , multiple drug allergy Patients impaired liver function ( Child Pugh B C base medical history ) Patients hemolysis/hemolytic anemia active bleeding/blood loss Major surgery intervention cause relevant blood loss inflammation within last 2 month Planned intervention surgery study might impact study objective . Febrile illness within 1 week first study drug administration clinically significant infection . Patients chronic inflammatory disease ( eg systemic lupus erythematosis , rheumatoid arthritis , Crohn´s disease ) could impact erythropoiesis persistent inflammatory activity ( eg Creactive protein ( CRP ) &gt; 20mg/L ) History thrombotic thromboembolic event ( e.g . myocardial infarction , stroke , transient ischemic attack , deep vein thrombosis , pulmonary embolism ) within recent 6 month Proliferative choroidal retinal disease , neovascular agerelated macular degeneration proliferative diabetic retinopathy require likely require treatment ( intraocular injection laser photocoagulation ) study . History myelodysplastic syndrome , multiple myeloma , bone marrow fibrosis , pure red cell aplasia . History hemosiderosis hemochromatosis . Patients history malignant disease last 5 year Treatment erythropoiesis stimulate agent ( ESA ) within last 4 week first intake study drug Intravenous iron substitution 2 week treatment period BAY 853934 RBC transfusion previous 8 week Use product contain carnitine and/or anabolics Use medicine substance oppose study objective might influence within 14 day first study drug administration Significant uncorrected rhythm conduction disturbance second thirddegree AV block without cardiac pacemaker episode sustain ventricular tachycardia Systolic blood pressure 100 160 mmHg prestudy visit Diastolic blood pressure 50 100 mmHg prestudy visit Positive result hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immune deficiency virus antibody ( antiHIV 1+2 ) prestudy visit Heart rate 110 bpm Ferritin level ≤ 30 ng/mL prestudy visit Transferrinsaturation &lt; 15 % prestudy visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Anemia</keyword>
</DOC>